Retatrutide1 is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. In clinical trials, retatrutide is taken as a once-weekly subcutaneous injection.
